{"doi":"10.1101/2022.03.02.22271746","title":"Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease","abstract":"Abstract In Alzheimer’s disease (AD), pathologic tau gradually progresses from initially circumscribed predilection regions to closely connected cortical regions. The pattern of tau-deposition is of critical importance for the clinical expression of AD, but the factors that underlie region-dependent susceptibility and resistance to tau pathology remain elusive. Motivated by brain-autopsy findings suggesting late thinly myelinated regions are the first to develop tau pathology, we investigated whether the level of myelination in fiber-tracts and cortex is predictive of region-specific tau accumulation. To address this hypothesis, we combined MRI-derived template of normative myelin distribution with tau-PET imaging from two independent samples of AD-biomarker characterized participants. We found that higher myelinated cortical regions show lower tau-PET uptake in spatially corresponding areas and regions connected by highly myelinated fiber-tracts show lower rates of tau spreading. These findings were independent of amyloid-PET levels. Together, our findings suggest that higher myelination is an important resistance factor against tau pathology in AD.","journal":"medRxiv","year":2022,"id":298581,"datarank":0.34475030701991616,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.07598638663570789,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.07598638663570789,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":4,"citers_with_citation_signal":4,"citers_with_endowment":4,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9508,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":84338,"name":"Nicolai Franzmeier","orcid":"0000-0001-9736-2283","position":1,"is_corresponding":false},{"id":253513,"name":"Anna Dewenter","orcid":"0000-0002-5636-196X","position":2,"is_corresponding":false},{"id":249999,"name":"Ying Luan","orcid":"0000-0003-3403-2353","position":3,"is_corresponding":false},{"id":226048,"name":"Ruben Smith","orcid":"0000-0001-7147-0112","position":4,"is_corresponding":false},{"id":229338,"name":"Olof Strandberg","orcid":null,"position":5,"is_corresponding":false},{"id":230944,"name":"Rik Ossenkoppele","orcid":"0000-0003-1584-7477","position":6,"is_corresponding":false},{"id":12191,"name":"Martin Dichgans","orcid":"0000-0002-0654-387X","position":7,"is_corresponding":false},{"id":65584,"name":"Oskar Hansson","orcid":"0000-0001-8467-7286","position":8,"is_corresponding":false},{"id":987604,"name":"Michael Ewers","orcid":"0000-0003-1856-9337","position":9,"is_corresponding":false},{"id":54260,"name":"Alzheimer’s Disease Neuroimaging Initiative (ADNI)","orcid":null,"position":10,"is_corresponding":false},{"id":232092,"name":"Anna Rubinski","orcid":"0000-0002-1768-1231","position":0,"is_corresponding":true}],"reference_count":63,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T00:31:36.269611Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}